CureVac NV
As of December 18, 2025, CureVac N.V. was acquired by BioNTech SE. CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRN… Read more
CureVac NV - Asset Resilience Ratio
CureVac NV (CVAC) has an Asset Resilience Ratio of 0.27% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how CureVac NV's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down CureVac NV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.12 Million | 0.27% |
| Total Liquid Assets | $3.12 Million | 0.27% |
Asset Resilience Insights
- Limited Liquidity: CureVac NV maintains only 0.27% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
CureVac NV Industry Peers by Asset Resilience Ratio
Compare CureVac NV's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for CureVac NV (2018–2024)
The table below shows the annual Asset Resilience Ratio data for CureVac NV.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.45% | $3.62 Million | $802.83 Million | +0.11pp |
| 2023-12-31 | 0.34% | $2.66 Million | $788.25 Million | -0.18pp |
| 2022-12-31 | 0.52% | $4.49 Million | $860.47 Million | +0.12pp |
| 2021-12-31 | 0.40% | $4.65 Million | $1.16 Billion | +0.23pp |
| 2020-12-31 | 0.17% | $2.62 Million | $1.51 Billion | -0.94pp |
| 2019-12-31 | 1.12% | $1.46 Million | $130.62 Million | -30.12pp |
| 2018-12-31 | 31.24% | $39.25 Million | $125.66 Million | -- |